decisionhealth Newsletters, Answer Books - 2006 Issue 3 (March)
Program_Memos / 2000 / AB-00-94
Subscribe or sign in to view the full article.
Article Overview
This 2000 HCFA Program Memorandum explains how a shortage of a thrombolytic agent affected care for ESRD dialysis patients with catheter occlusions. It is relevant to billing, reimbursement, and medical necessity review because it cites Medicare manual guidance on unlabeled drug use and distinguishes when thrombolytic treatment of different dialysis access types is separately billable or included under composite rate payment. The article is intended for Medicare intermediaries/carriers, dialysis providers, and coding or reimbursement staff who need to understand the general policy framework surrounding this shortage.
Why This Topic Matters
Dialysis facilities and Medicare reviewers needed updated operational guidance during the shortage so they could evaluate alternative therapies, document medical necessity, and apply the correct reimbursement framework for catheter-related thrombolytic treatment.
What You Will Learn
- How the shortage affected dialysis-related catheter treatment options
- What general Medicare guidance is cited for unlabeled drug use
- How the memorandum frames reimbursement treatment for thrombolytic therapy in dialysis access care
- Which types of organizations were expected to act on the memorandum
Who Should Read This
- Medicare intermediaries and carriers
- Dialysis facility billing staff
- Medical coders and reimbursement specialists
- Renal care providers
- Utilization review staff
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com